Since our last report, Brinavess has been on a roll. Enrollment was completed in the European Phase IV SPECTRUM study and data is expected by September in this 2,000 person post-approval trial.
Correvio Pharma Corp.'s (TSE:CORV): Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. With the latest financial year loss of -US$16.6m and a ...
The coronavirus disease 2019 (COVID-19) continues to afflict human communities across the globe. The best strategy to prevent severe symptoms of COVID-19 appears to be through establishing herd ...
Investors are always looking for growth in small-cap stocks like Correvio Pharma Corp (TSX:CORV), with a market cap of CA$105.66M. However, an important fact which most ignore is: how financially ...
One of China's leading COVID-19 vaccine candidates, called BBIBP-CorV, was shown to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday. A previous ...
Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ...
NEW YORK, Dec. 15, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Correvio Pharma ...
Correvio Pharma (CORV) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago. These figures are ...
The CORV local food team will release their 7th annual Central Ohio River Valley local food guide on Wednesday, April 16 in the Earth Day edition of CityBeat magazine. CORV is a grassroots effort to ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Correvio Pharma (CORV) reports results for the quarter ended December 2019. While this widely-known consensus outlook ...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results